See information from the 2022 ACR-FDA Summit.
This activity is designed for rheumatologists, physicians, clinicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in clinical research.
Upon completion of this activity, participants should be able to:
- Discuss ways to maintain interest in RA and PsA drug development
- Review innovative study designs, including use of novel outcome measures and patient reported outcomes (PROs)
View ACR-FDA 2022 Summit Program